Focusing on Risk Communication About Medicines: Why Now?

gan Bahri, Priya, Harrison-Woolrych, Mira
Cyhoeddwyd 2012

Listen to the public and fulfil their information interests – translating vaccine communication research findings into guidance for regulators

gan Bahri, Priya, Castillon Melero, Mireia
Cyhoeddwyd yn Br J Clin Pharmacol (2018)

Application of real-time global media monitoring and ‘derived questions’ for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines

gan Bahri, Priya, Fogd, Julianna, Morales, Daniel, Kurz, Xavier
Cyhoeddwyd yn BMC Med (2017)

Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Sta...

gan Bahri, Priya, Morales, Daniel R., Inoubli, Adrien, Dogné, Jean-Michel, Straus, Sabine M. J. M.
Cyhoeddwyd yn Drug Saf (2020)

The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products

gan Smith, Meredith Y., Russell, Andrea, Bahri, Priya, Mol, Peter G. M., Frise, Sarah, Freeman, Emily, Morrato, Elaine H.
Cyhoeddwyd yn Drug Saf (2017)

Patient Registries: An Underused Resource for Medicines Evaluation: Operational proposals for increasing the use of patient registries in regulatory assessments

gan McGettigan, Patricia, Alonso Olmo, Carla, Plueschke, Kelly, Castillon, Mireia, Nogueras Zondag, Daniel, Bahri, Priya, Kurz, Xavier, Mol, Peter G. M.
Cyhoeddwyd yn Drug Saf (2019)

Correction to: Patient Registries: An Underused Resource for Medicines Evaluation: Operational proposals for increasing the use of patient registries in regulatory assessments

gan McGettigan, Patricia, Alonso Olmo, Carla, Plueschke, Kelly, Castillon, Mireia, Nogueras Zondag, Daniel, Bahri, Priya, Kurz, Xavier, Mol, Peter G. M.
Cyhoeddwyd yn Drug Saf (2019)